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Objectives. The purpose of this study was to examine the 
clinical implications of administering thrombolytic therapy to 
menstruating women with acute myocardial infarction. 
Background. Although anecdotal case reports have suggested 
that thrombolytic therapy is safe during menstruation, the risk of 
increased bleeding in menstruating women receiving such therapy 
is poorly defined. 
Methods. We identified menstruating women who received 
thrombolytic therapy by soliciting information on all North 
American women enrolled in the GUSTO-I trial and then col- 
lected additional information about them with use of a one-page 
data form. We compared the characteristics and outcomes of these 
women with other GUSTO.I patient populations, including all 
North American women below the median age of menopause, all 
women and all patients. 
Results. The median age of the 12 menstruating women was 46 
years; 75% were cigarette smokers. The median hospital stay was 
7 days, 2 fewer than the overall stay in GUSTO-I. None of these 
women died or had a stroke or severe bleeding. Three patients 
(25%) had moderate bleeding (vaginal in two patients [66%]) that 
required transfusion compared with 11% of all GUSTO-I patients 
and all North American premenopausal women (p = 0.13) and 
17% of all female GUSTO-I patients (p = 0.47). Because of the 
small sample size of 12 women, the power was low (0.37) to detect 
the observed i[erence in moderate bleeding. The median nadir 
hematocrit was 33% in the menstruating women compared with 
34% in the premenopausal women and all women. The median 
time from symptom onset to treatment for the 12 women was 3.7 h, 
which was 0.9 h longer than the overall median in the trial (p = 
0.09). 
Conclusions. Although there was no statistically significant 
increase in bleeding risk during menstruation, this fact may be a 
result of low statistical power rather than a lack of effect. Thus, 
the results suggest that there may be a clinically significant 
increase in the risk of moderate bleeding. Nevertheless, the 
GUSTO.I experience is consistent with the concept that the 
lifesaving benefit of thrombolytic therapy for acute myocardial 
infarction should generally not be withheld because of active 
menstruation. 
(J Am Coil Cardiol 1995;26:1651-6) 
Each year in the United States ,-1.5 million people have a 
myocardial infarction; 33% of them are women, and -20% of 
these women are <65 years old. A total of -500,000 patients 
with myocardial infarction die in the United States annually; 
48% of them are women and -6,000 of these women are <65 
years old (1,2). Given an average menstrual cycle of 28 days 
and a 4-(_ 2-) day period of flow, 7% to 21% of premenopausal 
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women with a myocardial infarction could be menstruating at 
the time of presentation if myocardial infarction is equally 
likely at all times of the menstrual cycle (3). The indications 
and contraindications forthrombolytic therapy are commonly 
considered to be the same for men and women. Because active 
bleeding at presentation is a contraindication to thrombolytic 
therapy, many clinicians are uncertain whether menstruation 
should be classified as active bleeding and considered a
contraindication. 
Seven case reports (4-10) have been published escribing 
12 women who received thrombolytic therapy during menstru- 
ation; none of these patients were reported to have had serious 
bleeding or other adverse outcome. However, conclusions 
based on these anecdotal reports must be limited because of 
the small numbers and the possibility of reporting bias. 
Few data are available from clinical trials regarding the 
safety of thrombolytic therapy in menstruating women because 
these patients have often been excluded from such clinical 
trials, 1) because they are menstruating, and 2) because they 
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have child-bearing potential. The large scale Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for Oc- 
cluded Coronary Arteries (GUSTO-I) trial did not exclude 
such women from enrollment, thus providing an opportunity o
study the effects of thrombolysis in the 12 North American 
women reported to have been menstruating at the time of 
enrollment in the trial. The purpose of this study was to 
examine the baseline characteristics of these women and their 
outcomes, particularly with respect o bleeding complications, 
relative to those of the overall trial. 
Methods  
The GUSTO-I trial. The GUSTO-I trial has been de- 
scribed in detail previously (11). In brief, 41,021 patients with 
evolving acute myocardial infarction were randomized by 24-h 
toll-free hotline to one of four thrombolytic strategies: 1.5- 
million U streptokinase infused over 60 rain with subcutaneous 
heparin given twice daily in 12,500-U doses; 1.5-million U 
streptokinase over 60 rain with intravenous heparin given as a 
bolus of 5,000 U followed by an infusion of 1,000 U/h; 
accelerated recombinant tissue-type plasminogen activator 
(rt-PA) (bolus of 15 mg followed by 0.75 mg/kg body weight 
[maximum 50 rag] over 30 min followed by 0.5 mg/kg [maxi- 
mum 35 rag] over the next 60 min) with intravenous heparin 
given as with streptokinase; and a combination of streptoki- 
nase (1.0 million U over 60 rain) and rt-PA (1.0 mg/kg over 
60 rain [maximum 90 mg] with 10% given as a bolus) with 
intravenous heparin given as with streptokinase and acceler- 
ated rt-PA. 
Inclusion criteria were ST segment elevation ---0.1 mV in 
two or more limb leads (or ->0.2 mV in two or more contiguous 
precordial leads), onset of ischemic hest pain within 6 h of 
randomization, and no contraindications to thrombolytic ther- 
apy such as active bleeding or prior stroke. Exclusion criteria 
included recent major surgery and noncompressible vascular 
puncture to avoid exacerbating bleeding conditions. There was 
no exclusion for active menstruation. The primary outcome of 
the trial was 30-day mortality. 
Study patients. Women who had been menstruating at the 
time they were randomized into the GUSTO-I trial were 
identified through two avenues: 1) a toll-flee hotline set up to 
respond to clinical questions from North American sites, and 
2) an article encouraging the reporting of enrollment of 
actively menstruating women that was published in the North 
American edition of the December 1991 GUSTO-I Gazette, a
newsletter for all sites participating in the trial. Once the 
patients were identified, the study coordinators at the sites 
where these women were treated were sent a supplemental 
one-page data form asking for additional information, includ- 
ing the date menses began, any noted increase in menstrual 
flow after administration f thrombolytic agents and medical 
management practices. The perceptions of both the patients 
and the caregivers were requested. 
A comparison group was identified comprising all women 
<52 years old (the median age of menopause [3]) in the North 
American part of the trial who were not known to be menstru- 
ating at the time of enrollment. We also compared our study 
group with all women enrolled worldwide in GUSTO-I and 
with the entire GUSTO-I population with regard to baseline 
characteristics, bleeding and other complications and out- 
comes. 
Statistics. All categoric data are presented as number and 
percent; continuous data are presented as median and 25th 
and 75th percentiles. Univariable comparisons of the menstru- 
ating women with each of the other three groups were per- 
formed by using a chi-square test. A previously described 
mortality model (12) was used to estimate the risk of death in 
the 12 cases in our series. 
To address the issue of limited statistical power due to the 
small number of menstruating women, we determined the 
power to detect he observed increase (from 11% to 25%) in 
the rate of bleeding in 12 menstruating women compared with 
the rate in premenopausal non-menstruating women, and we 
determined the number of menstruating women that would be 
required to have an 80% chance of detecting a statistically 
significant (alpha <0.05) difference given the observed rates of 
bleeding. 
Resul ts  
Twelve women who had been actively menstruating at the 
time of enrollment into GUSTO-I were identified. They com- 
prised 1.3% of the 874 premenopausal women in North 
America enrolled in GUSTO-I and 0.1% of all 10,315 women 
enrolled. The total enrollment in GUSTO-I was 41,021 pa- 
tients. 
Demographics. The median age of the 12 menstruating 
women was 46 years, which equaled that of premenopausal 
North American women but was considerably ounger than 
the 67 and 62 years for all women and all patients in the trial, 
respectively (Table 1). Baseline characteristics for these 
women differed from those of the cohort of premenopausal 
age North American women in that they were more likely to 
have hypertension, previous myocardial infarction and inferior 
myocardial infarction. However, the two groups were similar 
with regard to cigarette smoking and family history of heart 
disease, having incidence rates that were considerably higher 
than those for all women and for all GUSTO-I patients. 
Although women enrolled into GUSTO-I were more apt than 
the entire patient population to have diabetes (21% vs. 15%), 
these 12 women and the premenopausal age women had the 
same incidence rate, which compared closely with that of the 
entire population (17% vs. 15%). 
The time between the onset of symptoms and receipt of 
thrombolytic therapy for the 12 menstruating women-- 
3.7 h--was almost 1 h longer than that (2.8 h) for the total 
GUSTO-I patient population and the cohort of premeno- 
pausal North American women; for all women patients itwas 
3.0 h. 
End points and bleeding complications. All 12 women 
survived the 1st 30 days (primary end point) and 1st year (one 
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Table 1. Baseline Demographic Data 
Menstruating Women Premenopausal Women All Women All GUSTO-I Patients 
(n = 12) (n = 874) (n = 10,315) (n = 41,021) 
Age (yr) 46 (42, 47) 46 (42, 49) 67 (59, 74) 62 (52, 70) 
Women 100% 100% 100% 25% 
Cigarette smoker 75% 80% 38% 43% 
Hypertension 50% 38% 50% 38% 
Hypercholesterolemia 45% 38% 38% 34% 
Diabetes 17% 17% 21% 15% 
Family history 67% 64% 44% 42% 
Previous MI 17% 9% 14% 16% 
Previous angina 36% 34% 39% 37% 
Previous CABG 0% 1% 3% 4% 
Previous PTCA 0% 4% 3% 4% 
Killip class 
I 90% 92% 82% 85% 
II 10% 7% 15% 13% 
III 0% 1% 2% 1% 
IV 0% <1% 1% 1% 
MI location 
Inferior 67% 58% 62% 60% 
Anterior 33% 38% 38% 40% 
Time to treatment (h) 3.7 (2.6, 4.9) 2.8 (2.1, 4.0) 3.0 (2.2, 4.2) 2.8 (2.0, 3.9) 
Onset to arrival 1.6 (1.0, 2.5) 1.4 (0.9, 2.3) 1.8 (1.0, 2.7) 1.5 (1.0, 2.5) 
Arrival to treatment 1.3 (1.1, 2.4) 1.3 (0.9, 1.8) 1.2 (0.8, 1.7) 1.1 (0.8, 1.6) 
Data are presented as median (25th, 75th percentiles) or percent of patients. CABG = coronary artery bypass graft 
surgery; GUSTO-I - the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary 
Arteries trial; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty. 
of the secondary end points) after their myocardial infarction 
(Table 2). According to the baseline characteristics of these 12 
women, the predicted 30-day mortality rate was only 2%, 
similar to the rate of 1.8% observed in the comparison group 
of women below the median age of menopause. None of the 12 
study subjects experienced a stroke. 
Although none of the menstruating women had severe 
bleeding complications, three were classified as experiencing 
moderate bleeding requiring a 2-U blood transfusion. Two of 
the three transfusions were for moderate vaginal bleeding; one 
of these women was in the accelerated rt-PA group and the 
other in the combination rt-PA-streptokinase group. The third 
transfusion was performed in a woman in the streptokinase 
plus subcutaneous heparin group because of a decrease in 
hematocrit. The incidence of moderate bleeding (3 [25%] of 
12) tended to be higher than that of premenopausal women 
and the total GUSTO-I population (11%, p = 0.14) and of all 
women in the trial (17%, p = 0.47). The nadir hematocrit was 
similar for the menstruating women and premenopausal 
women (33% vs. 34%, p = 0.639). 
Because of the small sample size of 12 menstruating 
women, the power to detect a statistically significant differ- 
ence--for example, an increase from 11% (in premenopausal 
women not known to be menstruating) to 25% compared with 
the rate in premenopausal nonmenstruating women--was only 
37%. A total of 70 menstruating women would be needed 
Table 2. Clinical End Points and Bleeding Complications* 
Menstruating Premenopausal All GUSTO-I All GUSTO-I 
Women Women Women Patients 
(n = 12) (n = 874) p Value (n = 10,315) (n = 41,021) 
Death within 30 days 0% (0%-25%) 1.8% (0.9%-2.7%) 0.63 11.3% (10.7%-11.9%) 7.0% (6.7%-7.2%) 
Death within 1 year 0% (0%-25%) 2.7% (0%-13.5%) 0.52 14.6% (7.7%-21.5%) 9.8% (6.9%-12.7%) 
Stroke 0% (0%-25%) 0.8% (0.2%-1.4%) 0.75 2.1% (1.8%-2.4%) 1.5% (1.3%-1.6%) 
Bleeding 
Severe: hemodynamically significant 0% (0%-25%) 2% (1.2%-3.1%) 0.60 2% (1.8%-2.3%) 1% (1.1%-1.3%) 
Moderate: required transfusion 25% (0.5%-50%)* 11% (0.9%-13%) 0.13 17% (16.4%-17.9%) 11% (11.1%-11.7%) 
Nadir hematocrit 33% (27%, 39%) 34% (30%, 38%) 0.64 34% (29%, 38%) 37% (33%, 41%) 
'Transfusion was required in two of the three women because of vaginal bleeding and in one woman because of decreased hematocrit. Data are presented as median 
values with 95% confidence limits with the exception of nadir hematocrit, which is presented as median value with 25th and 75th percentiles, p values compare 
menstruating women with premenopausal women. 
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Table 3. Procedures, Complications and Length of Stay 
Menstruating Premenopausal All GUSTO-I 
Women Women All Women Patients 
(n = 12) (n = 874) (n = 10,315) (n = 41,021) 
Procedures 
CABG 0~:~ 7% 8% 9% 
IABP 0~:; 4~ 4% 4% 
Cardioversion/defibrillation 17% 10% 10% 9% 
PTCA 42% 32% 22% 22% 
Pacemaker 8~ 7% 8% 7% 
Swan-Ganz catheterization 25~ 14% 14% 12% 
Ventilator 8c~,~ 10% 13% 11% 
Complications 
Fever. chills, allergic reaction g~ 6% 3% 4% 
Anaphylaxis 0q4 1% 1% 1% 
Hypotension 25 % 14% 17% 12% 
Atrioventricular block 8~ 9% 11% 8% 
Sustained ventricular tachycardia 8~ 5~4 6% 6% 
Ventricular fibrillation 8~,,~ 7% 7% 7% 
Asystole W4 3% 8% 6% 
Atrial fibrillation/flutter 8~ 4% 11% 9% 
Acute mitral regurgitation ()~ 2% 2% 1% 
VSD (}~'~ 1% 1% 1% 
Tamponade 0q} 1% 1% 1% 
Worst Killip class 
1 735~- 72% 58% 66% 
I1 275~ 21% 29% 25% 
III 0% 3% 6% 4% 
IV (1~ 3% 7% 5% 
Length of stay 7 days 8 days 9 days 9 days 
CABG = coronary, artery bypass graft surgery; IABP :: intraaortic balloon pump; PTCA = percutaneous 
transluminal coronary angioplasty; VSD = ventricular septal defect. 
before we could achieve 80% power to detect he observed 
difference of 25% versus 11%. 
Complications, procedures and length of stay. Five (42%) 
of the menstruating women underwent percutaneous translu- 
minal coronary angioplasty after their myocardial infarction, a
much higher ate than that of the entire GUSTO-I population 
(p = 0.10) and all women (p = 0.09) and moderately higher 
than that for the premenopausal cohort from North America 
(p = 0.48) (Table 3). The menstruating women also had a 
trend toward more frequent use of cardioversion/defibrillation 
(p = 0.42) and Swan-Ganz catheters (p = 0.26) and demon- 
strated a small increase in sustained hypotension (p = 0.29) 
compared with the rates in premenopausal women. 
The 12 women tended to be discharged earlier; their 
median length of stay in the hospital was 2 days shorter than 
that for all women (p = 0.06) and for the entire patient 
population (p = 0.09) and 1 day shorter than the length of stay 
for the women of premenopausal age (p = 0.38). 
Supplemental form. The results of the one-page supple- 
mental data form, which had a response rate of 100%, indi- 
cated that at enrollment and treatment two of the patients 
were having their first day of menstrual flow, four their second 
day and two their fourth day; one patient had been menstru- 
ating for 18 days and required a transfusion for vaginal 
bleeding and a decrease in hematocrit. The day of flow was 
unknown for three patients. Six (50%) of the 12 patients 
perceived no increase in their menstrual f ow after receiving 
thrombolytic therapy; information on 3 patients (25%) was not 
available. Although the remaining three patients (25%) noted 
an increase in flow, therapy was changed in response to this 
observation in just one of the three. This change was a 
reduction in the heparin infusion rate on day 4 after the 
myocardial infarction. The increase in menstrual flow in these 
three patients was not considered to represent a poor clinical 
outcome by their physicians. None of these women were 
treated with hormones to lessen the bleeding. 
Discuss ion 
Our study of 12 menstruating women given thrombolytic 
therapy in the GUSTO-I trial coupled with findings in the 12 
previously reported cases does not suggest an increase in risk 
of severe bleeding with thrombolytic therapy in this small 
subgroup of patients with acute myocardial infarction. Further- 
more, we found no evidence to suggest a difference in efficacy 
of therapy as assessed by clinical outcome and 1-year follow-up 
data. This group did not experience increased severe bleeding, 
stroke or a poorer clinical outcome than that of the GUSTO-I 
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Table 4. Published Case Reports of Similar Patients 
Study Pt Age Thrombolytic 
(ref no.) (yr) Agent Outcome 
Conti (4) 40 UK (intracorona~) No increased flow 
Chop et al. (5) 29 rt-PA Increased flow; shortened uration of menses 
de Gregorio et al. (6) 43 SK No increased flow; no adverse vents up to 
6 mo 
McCallister et al. (7) 43 rt-PA Less flow; shortened uration of menses; no 
adverse vents 
Simel et al. (8) 25* SK Less flow; no adverse vents up to 6 mo 
Lanter et al. (9) 48 rt-PA No increase in flow; no adverse vents 
Lanter et al. (9) 48 Accelerated rt-PA No increase in flow; no adverse vents 
Lanter et al. (9) 48 SK No increase in flow; no adverse vents 
Lanter et al. (9) 49 rt-PA No adverse vents 
Lanter et al. (9) 52 rt-PA No adverse vents 
Lanter et al. (9) 29 rt-PA No adverse vents 
Lee and Garza (10) 42 Accelerated rt-PA No adverse vents 
*This patient was treated for deep vein thrombosis rather than acute myocardial infarction. Pt = patient; ref = 
reference; rt-PA = recombinant tissue-type plasminogen activator; SK = streptokinase; UK = urokinase. 
population in general or of the subgroups of all women or of 
premenopausal North American women enrolled in the trial. 
However, the power to detect differences was small because of 
the small sample of menstruating women. 
As reported in the Myocardial Infarction Triage and Inter- 
vention Registry, 14% of women admitted with acute myocar- 
dial infarction were given thrombolytic therapy compared with 
26% of men, a statistically significant difference (p = <0.0001) 
that persisted after adjustment for age (13). One challenge to 
the cardiology community is to widen the indications for 
thrombolytic therapy in order to treat more patients who could 
potentially benefit from it. Studies published to date, including 
the present one, suggest hat menstruating women who meet 
inclusion criteria ought to receive thrombolytic therapy for 
acute myocardial infarction. 
The outcome of therapy was favorable in our 12 subjects 
and in the 12 patients previously reported (Table 4) (4-10). No 
patient died or had a stroke. The findings related to the 
menstrual period show no consistent patterns. The quantity of 
menstrual flow may have been affected by therapy (either 
increased or decreased flow) as may its duration (several 
patients reported shortened menstrual periods whereas most 
did not). 
Although all of our 12 subjects survived, all had very 
favorable baseline characteristics for survival (young age and 
stable hemodynamic status); the predicted 30-day mortality in 
this group was only 2% (12). Because of the small sample size, 
the 95% confidence interval for mortality in this group ranges 
from 0 to 25%; therefore, an increased risk of death in 
menstruating women is not excluded by this study. 
Because the bleeding in menses is predominantly due to 
sloughing of the endometrium induced by prostaglandin- 
mediated vasospasm of arterioles, the results (4-10) of the 
previously reported case studies suggested that the risk of 
bleeding would not be increased with the use of thrombolytic 
therapy. Detailed physiologic studies have demonstrated a 
high concentration of fibrinolytic enzymes in the endometrial 
fluid and a paucity of procoagulant substances, suggesting that 
systemic fibrinolytic agents might not increase bleeding (14- 
18). During the period of active sloughing (generally 12 to 18 h 
in the first portion of the menstrual cycle), the risk could 
theoretically be enhanced, but we found no evidence of 
substantially increased bleeding in the two women who re- 
ceived thrombolytic therapy on day 1 of the cycle. 
Despite these theoretic issues, the incidence of moderate 
bleeding in the 12 study patients was higher than expected and 
more than twice the rate of that in both the other premeno- 
pausal women in North America and the total GUSTO-I 
population. However, these bleeding episodes were not linked 
with any significant adverse outcome. 
With such a small sample size, it is difficult to draw 
conclusions about the increased time between the onset of 
symptoms and the administration of therapy in our 12 subjects. 
However, their prolonged median time to treatment (nearly 
1 h longer than that of the other patient groups in GUSTO-I) 
bears study in future trials to determine the causes for the 
delay. 
Limitations of the study. The limitation of this study in 
terms of small numbers is clear, and even with the 12 addi- 
tional reported cases we cannot rule out a possible modest 
increase in bleeding in menstruating women. The alternative of 
surveying all women enrolled in GUSTO-I who could have 
been premenopausal would provide a better estimate of the 
risks and benefits in this population but would require substan- 
tial resources. 
Conclusions. These results in conjunction with previous 
reports and theoretic onsiderations support he routine use of 
thrombolytic therapy in women during menstruation. The 
small increment in bleeding risk suggested by our study is not 
sufficient o offset he importance of salvaging myocardium and 
achieving a patent infarct-related artery to maximize the 
probability of long-term survival and quality of life (19,20). 
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